A recent Urology digest,
as sent to subscribers

Study Type: Systematic review with publication trend analysis (including RCT sub-analysis)

Key Question: What is the current volume, trajectory, and quality of evidence for AI applications in genitourinary oncology?

Key Findings:

• Publications grew from 14 (2013) to 362 (2023), with marked acceleration from 2019; the vast majority were retrospective (n=962 of 1220 included studies)
• Only 4 RCTs identified across the entire field — three in prostate cancer, one in urothelial cancer — covering diagnostics, prognostication, and treatment planning, all showing performance gains over conventional approaches
• Risk of bias varied across RCTs, primarily relating to randomisation methodology and intervention fidelity

Clinical Relevance: Despite widespread clinical interest in AI-assisted diagnostics and treatment planning for prostate, renal, and urothelial cancers, the evidence base underpinning NHS adoption decisions remains almost entirely observational.

Limitations: Only four RCTs were available for systematic review, making definitive conclusions about efficacy or safety impossible.

Study Type: Narrative review

Key Question: What are the pathological features, genomic characteristics, and treatment outcomes of the major histological subtypes and divergent differentiation patterns of urothelial carcinoma?

Key Findings:

• Histological subtypes are frequently understaged at TURBT and show high rates of lymph node metastasis, supporting early radical cystectomy even in some non-MIBC presentations
• Small cell UC responds consistently to platinum/etoposide; squamous, plasmacytoid, sarcomatoid, and micropapillary subtypes show variable and often inferior responses to standard systemic UC regimens
• Trimodality therapy may be equivalent to cystectomy in small cell UC but appears inferior for squamous and adenocarcinoma subtypes

Clinical Relevance: UK urologists managing variant histology bladder cancer should not apply standard MIBC treatment algorithms uniformly, as subtype-specific biology meaningfully alters staging, surgical timing, and systemic therapy selection.

Limitations: As a narrative review without meta-analysis, findings are subject to selection bias and lack quantified effect estimates from pooled data.

Study Type: Commentary/narrative review

Key Question: How does cancer and its treatment affect the risk, pathophysiology, and management of urolithiasis?

Key Findings:

• Cancer patients face distinct lithogenic risks including tumour lysis syndrome, hypercalcaemia, metabolic acidosis, and urinary stasis, compounded by systemic therapies and surgical anatomical alterations
• Urolithiasis is independently associated with increased rates of RCC, urothelial, and bladder cancer, potentially via chronic inflammation, recurrent infection, and shared metabolic risk factors
• PCNL is favoured for stone clearance in anatomically altered urinary tracts; RIRS and SWL have more limited, selective roles in this population

Clinical Relevance: UK urologists managing oncology patients — particularly post-cystectomy, post-nephrectomy, or on systemic therapies — should apply individualised metabolic evaluation and preventive strategies rather than standard stone protocols.

Limitations: Authors acknowledge a paucity of prospective data; current guidance is largely consensus- and expert-opinion-based rather than evidence-derived.

Study Type: Review article (narrative/mechanistic review)

Key Question: What is the role of CFTR in male spermatogenesis and sperm function, and could CFTR-targeted therapies improve fertility outcomes?

Key Findings:

• CFTR contributes to seminiferous tubular fluid homeostasis, blood-testis barrier integrity, and FSH signalling — not merely structural reproductive tract development
• Reduced CFTR expression is documented in spermatozoa from men with teratozoospermia, asthenozoospermia, and oligozoospermia, correlating positively with motility and morphology
• Even heterozygous CFTR variant carriers (conventionally regarded as healthy) may have measurably reduced sperm quality

Clinical Relevance: For UK urologists managing male-factor infertility, CFTR variants warrant consideration beyond CBAVD; this review supports broader CFTR genetic screening in unexplained sperm quality abnormalities and raises the prospect of CFTR modulators as a fertility treatment.

Limitations: As a narrative review, it does not provide pooled effect estimates; mechanistic claims rely substantially on animal and in vitro data with limited robust human clinical evidence.

Study Type: Phase 2 single-arm prospective trial

Key Question: Is intravesical gemcitabine/docetaxel (Gem/Doce) effective as first-line treatment in BCG-naïve high-risk NMIBC?

Key Findings:

• High-grade recurrence-free survival was 84% at 24 months (95% CI 63–94%) and 80% at 36 months (95% CI 58–91%) in 25 patients, median follow-up 50 months
• Cystectomy rate was 8% (2/25); no disease progression occurred during Gem/Doce treatment
• Grade-3 adverse events occurred in 20% of patients (predominantly haematuria and UTI); grade-1 events in 84%

Clinical Relevance: With ongoing BCG shortages affecting NHS practice, Gem/Doce represents a potential first-line bladder-preserving alternative for BCG-naïve high-risk NMIBC, with encouraging durability at 3 years.

Limitations: Small cohort (n=25) from a single-arm trial without a BCG comparator arm limits generalisability and interpretation of comparative efficacy.

Study Type: Retrospective matched cohort study

Key Question: Do younger patients (≤45 years) with NMIBC have different oncological outcomes compared to older patients?

Key Findings:

• Recurrence rates were significantly lower in younger patients (HR 1.53, 95% CI 1.09–2.14 favouring younger cohort, p=0.013)
• No significant difference in cancer-specific mortality, grade progression, progression to muscle-invasive disease, or metastasis between age groups
• Younger patients predominantly presented with low-grade (64%), Ta (82%), solitary tumours — a relatively favourable pathological profile

Clinical Relevance: Reassuring for UK urologists managing incidentally younger NMIBC patients; standard risk-stratified surveillance protocols appear oncologically appropriate rather than requiring age-specific escalation.

Limitations: Small younger cohort (n=124 after matching), single-country data with a notably elderly comparator group (median age 76), limiting generalisability to a typical NHS NMIBC population.

Study Type: Retrospective cohort study

Key Question: Does prostate volume or 5-ARI use influence grade progression and treatment decisions in men with GG1 prostate cancer on active surveillance?

Key Findings:

• Larger prostate volume was independently associated with reduced grade progression (HR 0.89 per 10cc, 95% CI 0.85–0.93) and reduced receipt of definitive treatment (HR 0.91 per 10cc, 95% CI 0.88–0.95)
• 5-ARI use was associated with significant reductions in grade progression (HR 0.80/year, 95% CI 0.72–0.89), extreme progression to ≥GG3 (HR 0.84), and definitive treatment (HR 0.53, 95% CI 0.41–0.67)
• Men with volumes >80cc had higher rates of bladder outlet procedures but remained safely managed within AS

Clinical Relevance: For UK urologists managing men on AS who also require BPH treatment, 5-ARIs appear safe and potentially oncologically beneficial, supporting their use within NHS active surveillance pathways.

Limitations: Retrospective design introduces selection bias; 5-ARI-related volume reduction may confound biopsy-based grade progression detection.

Study Type: Open-label randomised feasibility trial (RCT)

Key Question: Does phentermine/topiramate reduce uric acid stone burden in obese, diabetic patients with low urine pH?

Key Findings:

• Stone volume fell 52% in the intervention group versus an 8.6% increase in controls; statistically significant by per-protocol analysis (p=0.02), but not by intention-to-treat (p=0.10)
• Intervention group achieved greater weight loss (−10.2 vs +2.9 kg), improved urine pH (6.2 vs 5.5), and lower HbA1c (−0.2 vs +0.5%) compared to controls
• Medication was well tolerated with 73% adherence and no serious adverse events across 18 months

Clinical Relevance: Phentermine/topiramate may offer a novel systemic approach to uric acid stone dissolution in obese diabetic patients—a common phenotype in UK urology practice—addressing underlying metabolic drivers rather than stone alone.

Limitations: Very small sample (n=19, 15 completers) with a 2:1 allocation ratio limits statistical power and generalisability.